• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Multifocal intraocular lens a successful option

Article

Having a strong knowledge base of expected outcomes with a multifocal full-optic diffractive IOL will facilitate counseling prospective surgical candidates.

Having a strong knowledge base of expected outcomes will facilitate counseling prospective surgical candidates.

In it broadest sense and rather daunting implications, satisfaction may seem difficult to measure. However, one easy way to evaluate satisfaction is simply to ask, "Would you want to do that again?"

It's interesting that this satisfaction rate is very similar to that reported for LASIK: "The overall patient satisfaction rate after primary LASIK surgery was 95.4% (2,097 of 2,198 subjects; range of patient satisfaction for the 19 articles was 87.2% to 100%).2 That 19 out of every 20 patients will be satisfied with the outcomes of surgery should provide some initial confidence to surgeons trying a new technology for the first time.

The goal of presbyopia correction at the time of cataract surgery is spectacle independence. Again, from the FDA study, at 4 to 6 months postop, 88% of 292 subjects with the lens bilaterally implanted responded that they "never wear glasses."

That's an exciting result, and it leads to an important question. If they are in the 12% wearing glasses, why and for what purpose?

One consideration is correction of astigmatism. In the FDA study, investigator-surgeons were not allowed to perform adjunctive procedures to correct astigmatism like limbal-relaxing incisions (LRIs). (FDA has required this approach in every IOL study of which I am aware.)

© 2024 MJH Life Sciences

All rights reserved.